Patents by Inventor Phillip R. Hawkins

Phillip R. Hawkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5783669
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: July 21, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5776732
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human induced tumor protein (HITP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HITP. The invention also provides for the production and use of substantially purified HITP in pharmaceutical compositions to force differentiation and to stop cell division in cancerous cells. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HITP and the anti-HITP antibodies which specifically bind to HITP.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: July 7, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins
  • Patent number: 5773580
    Abstract: The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC. The invention also provides for the use of purified IPKC and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of IPKC. Additionally, the invention provides for the use of antisense molecules to ipkc in pharmaceutical compositions for treatment of diseases associated with the expression of IPKC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ipkc. The present invention also relates to anti-IPKC antibodies which specifically bind to IPKC.
    Type: Grant
    Filed: July 14, 1997
    Date of Patent: June 30, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5759812
    Abstract: The present invention provides a human selenium-binding protein (HSEBP) and polynucleotides which identify and encode HSEBP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSEBP and a method for producing HSEBP. The invention also provides for agonists and antibodies specifically binding HSEBP, and their use in the prevention and treatment of diseases associated with expression of HSEBP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSEBP for the treatment of diseases associated with the expression of HSEBP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HSEBP.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: June 2, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins
  • Patent number: 5747319
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human mRNA editing enzyme (REE). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding REE. The invention also provides for the use of substantially purified REE and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of REE. Additionally, the invention provides for the use of antisense molecules to REE in pharmaceutical compositions for treatment of diseases associated with the expression of REE. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding REE or anti-REE antibodies which specifically bind to REE.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: May 5, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5739009
    Abstract: The present invention provides a human adipocyte-specific differentiation-related protein (HADRP) and polynucleotides which identify and encode HADRP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HADRP and a method for producing HADRP. The invention also provides for agonists, antibodies, or antagonists specifically binding HADRP, and their use, in the prevention and treatment of diseases associated with expression of HADRP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HADRP for the treatment of diseases associated with the expression of HADRP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HADRP.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: April 14, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Phillip R. Hawkins
  • Patent number: 5712115
    Abstract: The present invention provides a polynucleotide which identifies and encodes a human cell death-associated protein (cdap) which was isolated from a rheumatoid synovium library. The invention provides for genetically engineered expression vectors and host cells comprising a nucleic acid sequence encoding CDAP. The invention also provides for the therapeutic use of purified CDAP, cdap or its antisense molecules, or CDAP inhibitors in pharmaceutical compositions and for treatment of conditions or diseases associated with expression of CDAP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.
    Type: Grant
    Filed: March 19, 1996
    Date of Patent: January 27, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Scott Michael Braxton, Lynn E. Murry
  • Patent number: 5676946
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel phospholipase C homolog (plch and PLCH). The present invention also provides for antisense molecules to the plch nucleotide sequences, expression vectors for the production of purified PLCH, antibodies capable of binding specifically to PLCH, hybridization probes or oligonucleotides for detecting excess PLCH-encoding nucleotide sequences, genetically engineered host cells for the expression of PLCH, diagnostic tests for activated, inflamed, diseased, and hydroxyurea-resistant cells and/or tissues based on PLCH-encoding nucleic acid molecules and antibodies capable of binding specifically to PLCH.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: October 14, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jeffrey J. Seilhamer
  • Patent number: 5663313
    Abstract: The present invention provides nucleic acid and amino acid sequences that identify and encode a novel human map kinase homolog (SMAP) expressed in cells of the human stomach. The present invention also provides for PCR oligomers or hybridization probes for the detection of nucleotide sequences encoding SMAP or SMAP-like molecules, antisense molecules to the nucleotide sequences which encode SMAP, diagnostic tests based on SMAP encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified SMAP, antibodies capable of binding specifically to SMAP, and agonists and inhibitors with specific binding activity for the polypeptide SMAP.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: September 2, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Janice Au-Young, Karl J. Guegler, Craig G. Wilde
  • Patent number: 5663059
    Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: September 2, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Lynn E. Murry
  • Patent number: 5650280
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel cellubrevin (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cb, expression vectors for the production of purified CB, antibodies capable of binding specifically to CB, hybridization probes or oligonucleotides for the detecting the upregulation of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CB, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CB.
    Type: Grant
    Filed: March 23, 1995
    Date of Patent: July 22, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer
  • Patent number: 5648238
    Abstract: The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC.
    Type: Grant
    Filed: June 18, 1996
    Date of Patent: July 15, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5648239
    Abstract: The present invention provides a polynucleotide (ipka) which identifies and encodes a novel human cAMP-dependent protein kinase A inhibitor homolog (IPKA). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKA.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: July 15, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jennifer L. Hillman, Janice Au-Young
  • Patent number: 5643752
    Abstract: The present invention provides a nucleic acid sequence which encodes a novel tissue inhibitor of metalloproteinases (TIMP-4) which was isolated from cells of human uterus. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding TIMP-4. The invention also provides for purified TIMP-4.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: July 1, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Lynn E. Murry
  • Patent number: 5633149
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization probes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: May 27, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Karl J. Guegler, Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5602008
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (ECs) from liver and pituitary gland tissues. The present invention also provides for antisense molecules to the nucleotide sequences which encode ECs, expression vectors for the production of purified ECs, antibodies capable of binding specifically to ECs, hybridization probes or oligonucleotides for the detection of EC-encoding nucleotide sequences, genetically engineered host cells for the expression of ECs, diagnostic tests for inflammation or disease based on on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs, pharmaceutical compositions to treat inflammation or disease based on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: February 11, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Craig G. Wilde, Phillip R. Hawkins, Olga Bandman, Jeffrey J. Seilhamer
  • Patent number: 5587301
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for the detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: December 24, 1996
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5587306
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel phospholipase C homolog (plch and PLCH). The present invention also provides for antisense molecules to the plch nucleotide sequences, expression vectors for the production of purified PLCH, antibodies capable of binding specifically to PLCH, hybridization probes or oligonucleotides for the detecting excess PLCH-encoding nucleotide sequences, genetically engineered host cells for the expression of PLCH, diagnostic tests for activated, inflamed, diseased, and hydroxyurea-resistant cells and/or tissues based on PLCH-encoding nucleic acid molecules and antibodies capable of binding specifically to PLCH.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: December 24, 1996
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jeffrey J. Seilhamer